Table 2.
Sample Characteristics.
|
Cannabis Users |
Controls |
|||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall |
NL |
TX |
Overall |
NL |
TX |
|||||||||||||||
| Median | MAD | Range | Median | MAD | Range | Median | MAD | Range | Median | MAD | Range | Median | MAD | Range | Median | MAD | Range | Results | Pairwise Comparisons | |
| N = 112; 42 % female | N = 64; 33 % female | N = 48; 54 % female | N = 90; 55 % female | N = 50, 54 % female | N = 36; 58 % female | Group | ||||||||||||||
| Age | 22 | 3 | 18–30 | 21 | 2 | 18–30 | 24 | 2 | 18–30 | 22 | 2 | 18–30 | 22 | 2 | 18–30 | 23 | 19–30 | Site*Group | 5* | |
| IQ | 22 | 3 | 7–30 | 21 | 3 | 7–30 | 23 | 2 | 16–30 | 25 | 3 | 12–35 | 23 | 3 | 12–30 | 26 | 2 | 17–35 | Site | |
| Education years | 14.5 | 1.5 | 5–20 | 15 | 2 | 7–20 | 14.25 | 2 | 5–20 | 16 | 1 | 10–23 | 17 | 1 | 12–23 | 16 | 2 | 10–21 | Group, Site | |
| Cannabis use measures | ||||||||||||||||||||
| CUD symptom count | 6 | 1 | 2–10 | 5 | 1.5 | 2–10 | 6 | 1 | 2–10 | – | – | – | – | – | – | – | – | – | ||
| Days of use (per week) | 7 | 0 | 5–7 | 7 | 0 | 5–7 | 7 | 0 | 5–7 | – | – | – | – | – | – | – | – | – | ||
| Typical grams/week | 7 | 3.5 | 0.275–35 | 5.6 | 2.6 | 0.275–21 | 8.4 | 2.25 | 0.7–35 | – | – | – | – | – | – | – | – | – | Site | |
| Age at first use | 16 | 1 | 11–27 | 15 | 1 | 11–18 | 16 | 2 | 12–27 | 17 | 2 | 13–21 | 17 | 1 | 14–21 | 19 | 0 | 13–20 | Group, Site | |
| Other substance use measures | ||||||||||||||||||||
| Lifetime illicit substance use (episodes) | 13 | 12 | 0–287 | 13 | 11.5 | 0–175 | 15 | 11 | 0–287 | 0 | 0 | 0–85 | 0 | 0 | 0–85 | 0 | 0 | 0–4 | Site*Group | 1*,3*,4* |
| Alcohol use and related problems (AUDIT) | 6 | 2 | 1–15 | 6 | 2 | 1–14 | 6 | 2.5 | 2–15 | 5 | 2 | 1–19 | 7 | 3 | 1–19 | 4 | 1 | 2–11 | Site*Group | 2*,3* |
| Daily smokers (%, N) | 32 % (36) | 51.6 % (33) | 6 % (3) | 16.7 % (15) | 28 % (14) | 2.8 % (1) | Site, Group | |||||||||||||
| Well-being measures | ||||||||||||||||||||
| Depression (BDI) | 9 | 6 | 0–39 | 8.5 | 5.5 | 0–34 | 10 | 6.5 | 0–39 | 5 | 4 | 0–31 | 6 | 3 | 0–23 | 5 | 4 | 0–31 | Group | |
| Anxiety (STAI-Trait) | 39.5 | 8.5 | 20–64 | 38 | 7 | 20–63 | 41 | 9 | 21–64 | 33 | 6 | 22–65 | 32 | 5 | 22–55 | 35.5 | 6.5 | 22–65 | Group | |
| ADHD (ASRS) | 14 | 3 | 3–22 | 16 | 2 | 10–22 | 10.5 | 2.5 | 3–21 | 13 | 3 | 3–23 | 15 | 2 | 10–23 | 9 | 3 | 3–18 | Group, Site | |
| DSM 5 Cross Cutting Symptoms (count) | 14 | 6 | 1–45 | 13.5 | 6 | 1–37 | 14.5 | 6.5 | 3–45 | 9 | 3 | 0–34 | 9.5 | 3.5 | 1–21 | 8 | 3 | 0–34 | Site*Group | 1*,3*,4* |
| Cannabis Attitudes | ||||||||||||||||||||
| Positive Personal | 26 | 2 | 6–30 | 24 | 3 | 6–30 | 27 | 27 | 22–30 | 18 | 3 | 10–28 | 17 | 2 | 10–28 | 18.5 | 3.5 | 10–25 | Group*Perspective; Site*Perspective | |
| Positive Family/Friends | 20 | 3 | 7–30 | 19.5 | 2.5 | 7–29 | 23 | 23 | 12–30 | 17 | 3 | 6–26 | 17 | 2 | 10–24 | 18 | 4.5 | 6–26 | ||
| Positive State/Country | 17 | 3 | 7–27 | 16.5 | 2.5 | 9–26 | 18 | 18 | 7–27 | 16 | 2 | 7–25 | 16 | 2 | 11–25 | 15 | 3 | 7–24 | ||
| Negative Personal | 15 | 3 | 6–25 | 16 | 3 | 7–25 | 12 | 12 | 6–20 | 19 | 4 | 8–28 | 20 | 3 | 8–27 | 18 | 3 | 9–28 | Site*Group Group*Perspective | 1** |
| Negative Family/Friends | 18 | 3 | 8–30 | 19 | 3 | 11–30 | 16.5 | 16.5 | 8–24 | 20.5 | 3 | 11–30 | 21 | 3 | 11–29 | 19.5 | 4.5 | 13–30 | ||
| Negative State/Country | 23 | 3 | 11–30 | 24 | 2 | 11–30 | 22 | 22 | 11–30 | 23 | 3 | 13–30 | 22 | 3 | 13–30 | 24 | 3 | 16–30 | ||
Note. CUD = Cannabis Use Disorder; AUDIT = Alcohol Use Disorder Identification Test; ADHD = Attention Deficit Hyperactivity Disorder; BDI = Beck Depression Inventory; STAI = State Trait Anxiety Inventory; ASRS = Adult Self-Report Scale; 1: TX CAN-NL CAN, 2: TX CON-NL CON, 3: TX CAN-TX CON, 4: NL CAN-NL CON, 5: TX CAN-NL CON, 6: NL CAN-TX CON; *Significance threshold p =.05; **Significance threshold P =.05/28.